Efficacy of respiratory quinolones for the treatment of community acquired pneumonia: a randomized controlled trial of moxifloxacin versus garenoxacin.
- Conditions
- Community acquired pneumonia
- Registration Number
- JPRN-UMIN000005515
- Lead Sponsor
- agasaki evaluation organization for clinical interventions
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 120
Not provided
1.Patients who are prohibited to take either moxifloxacin or garenoxacin. 2.Low body weight (less than 40 kg). 3.Severe renal dysfunction (Ccr is less than 30 mL/min, or eGFR is less than 30 mL/min). 4.Patients with history of convulsant disease such as epilepsy. 5.Patients who took quinolones for current pneumonia. 6.Patients with episodes of apparent aspiration. 7.Patients with severe underlying diseases such as advanced cancer, primary lung cancer, metastatic lung cancer, severe heart failure and severe respiratory failure. 8.Patients with cystic fibrosis, AIDS, pneumocystis pneumonia, or active pulmonary tuberculosis. 9.Patients with pneumonia severity of PORT score V. 10.Patients whose participation in the study may put them at disadvantages.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method